Use your antibodies-online credentials, if available.
抗Human MPL 抗体:
抗Mouse (Murine) MPL 抗体:
抗Rat (Rattus) MPL 抗体:
Human Monoclonal MPL Primary Antibody for FACS, WB - ABIN967682
Broudy, Lin, Fox, Taga, Saito, Kaushansky: Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. in Blood 1996
Show all 4 Pubmed References
Human Monoclonal MPL Primary Antibody for FACS, ELISA - ABIN969542
Marty, Chaligné, Lacout, Constantinescu, Vainchenker, Villeval: Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. in The Journal of biological chemistry 2009
Show all 2 Pubmed References
Human Polyclonal MPL Primary Antibody for IF (p) - ABIN2177733
Maekawa, Osawa, Izumi, Nagao, Takano, Okada, Tachi, Teramoto, Kawamura, Horiuchi, Saga, Kato, Yamamura, Watanabe, Kobayashi, Kobayashi, Sato, Hashimoto, Suzu, Kimura: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis. in Leukemia 2017
Results show that mutant CALR (显示 CALR 抗体) induces autocrine, but not paracrine activation of MPL in myeloproliferative neoplasm. [review]
these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking.
Coexisting mutations of the JAK2 (显示 JAK2 抗体), CALR (显示 CALR 抗体), and MPL genes in myeloproliferative neoplasms suggest that CALR (显示 CALR 抗体) and MPL should be analyzed not only in JAK2 (显示 JAK2 抗体)-negative patients but also in low V617F mutation patients.
identification of a higher frequency of co-existing JAK2 (显示 JAK2 抗体) exon-12 or MPL exon-10 mutations in patients with myeloproliferative neoplasms with a low JAK2V617F allelic burden compared to those with a higher allelic burden.
A newborn girl with congenitcal amegakaryocytic thrombocytopenia had a homozygous missense Trp154-to- Arg mutation in exon 4 of c-MPL. The same heterozygote mutation was detected in her mother, father, and 2 siblings.
Mutation status of JAK2 (显示 JAK2 抗体), CALR (显示 CALR 抗体), and MPL in essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Normal FLT3 (显示 FLT3 抗体) and negative expression of CD34 (显示 CD34 抗体) and cMPL may predict a longer overall survival in aute myeloid leukemia (显示 BCL11A 抗体).
we show that the positive charge of the CALR (显示 CALR 抗体) mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR (显示 CALR 抗体) and the thrombopoietin receptor MPL.
Anagrelide proved effective among all molecular subsets, indicating that JAK2 (显示 JAK2 抗体)/CALR (显示 CALR 抗体)/MPL mutational status does not seem to represent a major determinant of choice of cytoreductive treatment among essential thrombocythemia therapies.
In essential thrombocythemia, MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2 (显示 JAK2 抗体)/MPL mutations with higher risk of thrombosis.
C-Mpl is expressed on osteoblasts and osteoclasts and is important in regulating skeletal homeostasis.
CALR (显示 CALR 抗体) mutants are sufficient to induce thrombocytosis through MPL activation.
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin (显示 CALR 抗体) mutants.
The interaction between Mpl and Atp5d (显示 ATP5D 抗体) was confirmed by the yeast two-hybrid system, mammalian two-hybrid assay, pull-down experiment, and co-immunoprecipitation study in vivo and in vitro.
Mouse prenatal platelet-forming lineages share a core transcriptional program but divergent dependence on MPL.
MERIT40 (显示 BABAM1 抗体) deficiency triggers hypersensitivity to Tpo (显示 THPO 抗体) stimulation and the stem cell phenotypes are abrogated on a background null for the Tpo (显示 THPO 抗体) receptor Mpl.
OTT1 regulates the alternative splicing of Mpl-TR, a truncated isoform of c-Mpl, which modulates Thrombopoietin (显示 THPO 抗体)-mediated signaling.
Mpl expression, but not Tpo (显示 THPO 抗体), is fundamental in the development of JAK2V617F(+) myeloproliferative neoplasms
Thrombopoietin (显示 THPO 抗体)/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 (显示 MECOM 抗体) leukemia.
In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.
, myeloproliferative leukemia protein
, proto-oncogene c-Mpl
, thrombopoietin receptor
, myeloproliferative leukemia virus oncogene
, thrombopoietin receptor-like
, cytokine receptor
, myeloproliferative leukemia virus oncogene, like
, thrombopoietin receptor c-mpl